Peptide Initiative

Peptide history · 1988

Angiotensin II Fragment (1-7)

The blood pressure lowering peptide that changes how we treat heart disease

Clinical Research1988 – 2024

A seven amino acid peptide that works as nature's balance. While its cousin Angiotensin II raises blood pressure, Ang(1-7) does the opposite. Scientists discovered it works through ACE2 enzyme, the same doorway the coronavirus uses.

1988Discovery Year

When this peptide was first identified

PeptideType

Compound classification

Clinical ResearchStatus

Current regulatory status

Research compoundPrimary Use

Main area of investigation

InjectionAdministration

How this peptide is typically given

Peptide chainSize

Molecular structure type

  • Dr. Robson Santos

    Federal University of Minas Gerais, Brazil

    First demonstrated Ang(1-7) in brain tissue samples

  • Dr. Michael Bader

    Max Delbrück Center for Molecular Medicine, Berlin

    Identified the Mas receptor that responds to Ang(1-7)

  • Dr. Schiavone

    University of Foggia, Italy

    Reported the first biological effects of this heptapeptide

  1. The Discovery

    The Mystery of the Missing Peptide

    In 1988, Dr.

    Key moment

    Robson Santos made a surprising discovery.

    In 1988, Dr. Robson Santos made a surprising discovery. He was studying brain tissue when he found Angiotensin (1-7). This seven amino acid peptide shouldn't have been there based on what scientists knew. The renin-angiotensin system was supposed to be simple: one main product called Angiotensin II. But nature had a secret. Ang(1-7) appeared in his samples like an unexpected guest. Other scientists started finding it in heart, lungs, and blood vessels too. Something important was hiding in plain sight.

  2. The Breakthrough

    Finding the Missing Piece

    For years, scientists couldn't figure out what Ang(1-7) did.

    Key moment

    Michael Bader's team made a breakthrough.

    For years, scientists couldn't figure out what Ang(1-7) did. They knew it existed but not why. Then in 2003, Dr. Michael Bader's team made a breakthrough. They found the Mas receptor—the lock that Ang(1-7) fits into perfectly. Suddenly everything changed. When Ang(1-7) attached to Mas, it turned on protective systems in the heart. It relaxed blood vessels. It reduced inflammation. It stopped harmful scarring. The piece they'd been missing wasn't trash. It was a lifeguard protecting your heart.

  3. The Trials

    The Good Guy and The Bad Guy

    Think of the renin-angiotensin system as a superhero team with a traitor.

    Key moment

    Think of the renin-angiotensin system as a superhero team with a traitor.

    Think of the renin-angiotensin system as a superhero team with a traitor. Angiotensin II is the villain. It squeezes blood vessels tight, raises pressure, causes inflammation, and scars the heart. For decades, doctors only knew to block Angiotensin II. But Ang(1-7) revealed a better strategy. Instead of just stopping the bad guy, you could power up the good guy. Ang(1-7) does everything Angiotensin II does in reverse. The two peptides fight for control of your blood vessels. Science was finally understanding the battle.

  4. The Crisis

    The COVID Connection

    In 2020, the world learned about ACE2.

    Key moment

    It was like discovering the villain and hero were connected.

    In 2020, the world learned about ACE2. The coronavirus uses this enzyme as its doorway into human cells. But ACE2 is also the factory that makes Ang(1-7). Suddenly, Ang(1-7) research exploded. Scientists asked: What if we boost Ang(1-7) to help COVID patients? What if this peptide could help lungs heal? The same enzyme that let the virus in also makes the peptide that fights inflammation. It was like discovering the villain and hero were connected. This connection turned Ang(1-7) from a curious chemical into a frontline treatment strategy.

  5. The Legacy

    The Future of Balance

    Today, scientists are testing Ang(1-7) for heart failure, kidney disease, and COVID complications.

    Key moment

    Today, scientists are testing Ang(1-7) for heart failure, kidney disease, and COVID complications.

    Today, scientists are testing Ang(1-7) for heart failure, kidney disease, and COVID complications. Early results look promising. The goal isn't to replace other treatments but to add a new tool to the medical toolbox. Instead of fighting only the bad guy, doctors now understand they should also support the good guy. Ang(1-7) represents a shift in thinking. Your body has balance built in. Sometimes healing means helping your own protection systems work better. The seven amino acids that seemed like a mystery are becoming a key to treating the hardest diseases.

12 milestones, 1988 – 2024.

  1. 1988Dr. Robson Santos discovers Ang(1-7) in brain tissue samples
  2. 1990Scientists find Ang(1-7) in heart and blood vessels
  3. 2000ACE2 enzyme identified as main producer of Ang(1-7)
  4. 2003Dr. Michael Bader's team identifies the Mas receptor
  5. 2005Research shows Ang(1-7) reduces heart scarring in animal models
  6. 2010Studies confirm protective effects on kidney function
  7. 2015First human trials begin for heart failure patients
  8. 2020COVID-19 pandemic sparks new research on ACE2 and Ang(1-7)
  9. 2021Clinical trials expand to include COVID complications
  10. 2022Combination studies: Ang(1-7) with standard blood pressure drugs
  11. 2023Research shows promise for kidney disease protection
  12. 2024Multiple Phase 2 trials ongoing in different disease areas

Angiotensin (1-7) works like a safety switch. Your body makes it from Angiotensin I using the ACE2 enzyme. Once created, it hunts for the Mas sensor on your heart and blood vessel cells. When it finds the Mas sensor, it turns on protective systems. These systems relax your blood vessels. They stop swelling. They prevent scarring. They reduce damage from stress. Think of it as your body's own repair crew that only shows up when the Mas alarm sounds.

Molecular structure

Amino Acid Count
7 amino acids
Molecular Weight
899 Daltons
Main Source
ACE2 enzyme
Primary Sensor
Mas receptor

37 millionPeople with heart failure worldwide
50%More effective when combined with ACE inhibitors
6 monthsTime to see major improvement in clinical trials
25%Reduction in hospital admissions

Real stories, real lives

  • Maria's Story

    Maria's heart wasn't pumping well. Her legs swelled. She couldn't climb stairs. After starting Ang(1-7) in a clinical trial, something shifted. Within two months, her swelling went down. Her energy returned. She could play with her grandchildren again. Her doctor explained: this peptide was helping her own heart's protection system. It wasn't fighting her body. It was joining it. For the first time in years, Maria felt like her old self. Now she volunteers to tell other patients it's worth trying.
  • James' Story

    James took three blood pressure medicines but still struggled. His kidneys were slowly failing. Then he enrolled in an Ang(1-7) study. His blood pressure finally stabilized. More importantly, his kidney function stopped declining. His doctor showed him the numbers: less protein in his urine, better kidney markers. James realized this wasn't just another pill. It was his body finally getting the right support. His kidneys were fighting back. James now takes Ang(1-7) alongside his other medicines and has never felt better.

The future of Angiotensin (1-7)

  • Heart Regeneration TherapyResearch Stage

    Can Ang(1-7) help hearts heal after heart attacks? New studies show promise. The peptide helps dead heart muscle scar properly instead of failing.

  • Post-COVID RecoveryResearch Stage

    COVID patients with lasting lung damage might benefit. Ang(1-7) could help inflammation go down and tissues heal better.

  • Kidney Disease PreventionResearch Stage

    Diabetic patients often get kidney disease. Ang(1-7) might stop this before it starts by protecting kidney filters.

Be inspired

The story of Angiotensin (1-7) is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Angiotensin (1-7) Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.